Aims Studies on the glycoprotein IIb-IIIa receptor blocker abciximab in patients undergoing percutaneous coronary intervention consistently show a reduction in procedurerelated myocardial infarction. Some such infarcts are characterized by elevated creatine kinase or creatine kinase-MB, without apparent clinical symptoms. The clinical relevance of such 'creatine kinase leaks' has been questioned. Therefore we investigated the relationship between postprocedural creatine kinase-MB elevation and outcome at the 6 month follow-up.
Introduction
Studies in patients undergoing percutaneous coronary intervention and taking glycoprotein IIb-IIIa receptor antagonists consistently show improved outcome compared to those on placebo [1] [2] [3] [4] [5] . This was most noticeable in the 50% reduction in the incidence of myocardial infarction in three studies with abciximab in different patient populations. The CAPTURE (Chimeric 7E3 Antiplatelet Therapy in Unstable angina Refractory to standard treatment) investigators compared abciximab with placebo in patients with refractory unstable angina in spite of ongoing treatment with heparin and nitrates [1] . The EPIC (Evaluation of c7E3 Fab in the Prevention of Ischemic Complications) study included patients undergoing angioplasty considered 'high risk', based on clinical or angiographic features [2] , while the EPILOG (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade) study addressed the value of abciximab in patients undergoing elective 'non-high risk' coronary angioplasty [3] . The major effect in these three studies, which included the full spectrum of patients undergoing coronary angioplasty, was a reduction in death or myocardial infarction at 30 days follow-up, from 9·0% to 4·8% (CAPTURE); from 9·6% to 6·1% (EPIC) and from 9·1% to 4·0% (EPILOG). The infarcts mostly occurred at the time of angioplasty. Infarcts occurring in association with the angioplasty procedure were defined by an increase in creatine kinase-MB, or total creatine kinase, more than three times the upper limit of normal. Infarcts not associated with the procedure were defined by a creatine kinase-MB or total creatine kinase increase exceeding twice the upper limit of normal. Some reports suggest that small infarcts occurring at the time of angioplasty are associated with impaired prognosis [6] [7] [8] , while others questioned whether the 'infarcts' do in fact represent significant myocardial damage or should be considered as insignificant 'creatine kinase leak' [9] . In order to investigate this issue, a detailed analysis was performed of the outcome of groups of patients with different levels of creatine kinase elevation after PTCA in the three studies [1] [2] [3] . The results confirm that even a modest rise in creatine kinase, which may be labelled as minor myocardial damage after PTCA, is indeed associated with a poor outcome in the subsequent 6 months. Possible explanations for this observation are presented.
Methods
The three studies, CAPTURE, EPIC and EPILOG, were conducted by different groups of investigators, who applied similar end-point definitions. The protocols, procedures and study results have been presented in detail [1] [2] [3] . Patients were selected with refractory unstable angina (CAPTURE), undergoing high risk PTCA on angiographic or clinical criteria (EPIC), or undergoing elective PTCA (EPILOG). All patients received aspirin as well as heparin i.v. at standard dosage (EPIC) or reduced dosage (CAPTURE, EPILOG). Patients were also randomized to either abciximab or placebo. In CAPTURE the study drug was administered from 18-24 h preceding angioplasty until 1 h after the procedure, and in EPIC and EPILOG from 1 h before until 12 h after angioplasty. One group of patients in EPIC received a bolus of abciximab only.
The primary end-point in these three studies was the occurrence of death, myocardial infarction or urgent (re) intervention within 30 days. All clinical data, electrocardiograms and serum enzyme results were analysed by clinical event committees, which assessed whether or not myocardial infarction had occurred, independent from the investigators. This was considered important since the investigators may have underestimated the incidence of myocardial infarction, particularly small infarcts, associated with the procedures they performed. Myocardial infarction during the index hospital stay was defined as values of creatine kinase or its MB isoenzyme more than three times the upper limit of normal in at least two samples and increased by 50% over the previous value, or an ECG with new significant Q waves in two or more contiguous leads. Myocardial infarction after discharge was defined by concentrations more than twice the upper limit of normal of creatine kinase or its MB isoenzyme, or new significant Q waves in two or more contiguous ECG leads. In order to distinguish between events causing an elevated creatine kinase-MB or creatine kinase level in association with the PTCA procedure, and new events during follow-up, the present analysis assessed specifically the relationship between periprocedural enzyme elevations, occurring within 48 h of PTCA, and subsequent new events with an onset >48 h after PTCA, as determined by independent clinical event committees.
Data analysis
Creatine kinase-MB and total creatine kinase were analysed at the participating hospitals. Values were transformed to creatine kinase-MB and creatine kinase ratios, relative to the upper limit of normal in each hospital. For the present investigation, patients were subdivided into three groups according to their peak creatine kinase-MB ratio after angioplasty: ratio <1, ratio 1-3, and ratio d3 times the upper limit of normal. These enzyme categories are indicated as, respectively, normal, minimal myocardial damage, and myocardial infarction. In additional analyses the latter group was subdivided into three categories (ratios 3-5, 5-10 and d10) yielding a total of five enzyme categories. In the multivariable analysis creatine kinase-MB or creatine kinase ratios were entered as continuous variables. When available, creatine kinase-MB was the preferred measurement for the analysis. Patients were excluded from the analysis if they had elevated baseline creatine kinase or creatine kinase-MB (>1·5 times upper limit of normal), if they were classified as having a preprocedure myocardial infarction, or if pre-or post-procedure creatine kinase or creatine kinase-MB values were absent. Creatine kinase-MB or creatine kinase values obtained within 48 h before the start of PTCA were considered periprocedural or baseline enzyme values, and creatine kinase-MB or creatine kinase measurements within 48 h after the start of PTCA were considered post-procedure values.
Statistical analyses
Data were analysed with the SAS statistical software package. Continuous variables were summarized by means and standard deviations, unless described otherwise. Categorical variables were summarized by counts and/or percentages. Fisher's exact test was used to assess differences in categorical variables with respect to enzyme category. Differences in variables with an ordinal scale were assessed with the Chi-square test according to Mantel-Haenszel. Multivariable logistic modelling was used to examine relationships between binary outcome variables and predictor variables: age, weight, previous CABG, previous congestive heart failure, diabetes, previous hypercholesterolaemia, previous hypertension, lesion characteristics, previous myocardial infarction, pre-PTCA thrombus, multiple native vessels treated, study (CAPTURE, EPIC, EPILOG),
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randomized to abciximab and the log enzyme ratio. The log enzyme ratio was entered into this analysis as a continuous variable in order to account for the nonnormal distribution of the enzyme ratios. Variable selection was done in a stepwise fashion. The difference in event-free survival time between the different patient groups was evaluated by the Kaplan-Meier method with the log rank test.
Results
A total of 6156 patients were enrolled in the three studies. One hundred and five patients in whom no PTCA was attempted were excluded from the current analysis, as were 285 patients with elevated baseline creatine kinase-MB or creatine kinase exceeding 1·5 times the upper limit of normal prior to the procedure, 25 patients with onset of infarction before start of the PTCA procedure, and 716 patients with missing pre-or post-procedure creatine kinase-MB or creatine kinase values. Thus a total of 5025 patients representing 82% of the whole study population were available for analysis.
Of this population 4034 patients had post-procedure peak enzymes lower than the upper limit of normal, 662 had a small rise in creatine kinase-MB or creatine kinase between 1·0 and 3·0 times the upper limit of normal, while 329 patients had enzyme elevations exceeding three times the upper limit of normal after the angioplasty procedure, classified as myocardial infarction. Baseline characteristics of these three groups of patients, classified according to peak creatine kinase-MB or creatine kinase ratio, and of the excluded patients, are presented in Table 1 . Patients without elevated enzymes had fewer previous infarctions and had undergone less bypass surgery, had less thrombus visible before PTCA, had fewer severe lesion characteristics and were more often randomized to abciximab.
PTCA was attempted in all 5025 patients, and was successful, with a residual diameter stenosis of less than 50% in 4692 patients (93·4%). Elevated enzymes were associated with a lower PTCA success rate (Table 1) . Only 259 out of 329 patients (78·7%) with a creatine kinase-MB ratio d3 had an angiographically successful PTCA. Stents were used in 463 patients (9·2%) for treatment of coronary occlusion, extensive dissection or otherwise unsatisfactory angiographic outcome. More stents were used in patients with elevated creatine kinase-MB or creatine kinase ratio.
There was a consistent gradual increase in 30-day mortality as well as in 6-month mortality related to the post-procedural creatine kinase-MB level (Fig. 1) . Sixmonth mortality increased from 1·1% in patients with a normal creatine kinase-MB ratio, up to 4·0% in patients [1] [2] [3] ; CABG=coronary bypass surgery; CHF= congestive heart failure; PTCA=percutaneous transluminal coronary angioplasty; MI=myocardial infarction. Procedure success=residual diameter stenosis <50% after PTCA.
*Significant difference between different enzyme categories (Fisher Exact test P<0·05).
whose creatine-kinase-MB ratio or creatine kinase was more than three times normal (Table 2 ). For patients with creatine kinase-MB or creatine kinase ratios 1-3 and 3-5, 5-10, and d10, 6-month mortality was 2·1% and 1·8%, 3·6% and 6·7%, respectively. This trend was highly significant, (P=0·001). Similar to mortality, the incidence of death or recurrent infarction was related to the level of periprocedural creatine kinase-MB or creatine kinase ratio (Figs 1 and 2) . Non-fatal reinfarction occurred more frequently in patients with an elevated Major events at 30 days and at 180 days follow-up in groups of patients with different levels of creatine kinase-MB or creatine kinase elevation after PTCA. Only events occurring >48 h after PTCA are included. The three columns on the right are a subdivision of patients with a periprocedural infarct (creatine kinase-MB or creatine kinase ratio d3). *Significant difference between different enzyme categories (Fisher Exact test, P<0·05).
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creatine kinase-MB ratio 1-3, 3-5 and 5-10 (P<0·001), although no non-fatal infarcts occurred in patients with creatine kinase-MB ratio d10. A separate analysis of the three lowest enzyme categories (<1, 1-3, 3-5) confirmed a gradual increase in mortality at 30 days and 6 months (P=0·019 and P=0·078) as well as mortality or myocardial infarction (P=0·001 and P=0·01 at 30 days and 6 months respectively). The time course of mortality according to peak creatine kinase-MB or creatine kinase ratio is depicted in Fig. 2 . It is evident that many deaths occurred early, in the first 2 weeks after the intervention (20 patients), but also that deaths continued to occur throughout follow-up (53 patients), both in patients with elevated creatine kinase-MB or creatine kinase ratio (d3) but also in patients with minimal myocardial damage (creatine kinase-MB or creatine kinase ratio between 1 and 3). An additional analysis revealed the same trends after exclusion of patients with unsuccessful PTCA according to local investigators, and of patients who received a stent (Table 3) . Patients with minimal myocardial damage (creatine kinase-MB or creatine kinase ratio 1-3) or small infarcts (creatine kinase-MB or creatine kinase ratio 3-10) were at a higher risk of death or infarction even after the first week (P=0·016 and P=0·001, respectively) or more than 1 month after PTCA (P=0·038 and P<0·001, respectively).
Causes of death are summarized in Table 4 , and included eight deaths from myocardial infarction, 14 sudden deaths and 12 related to a subsequent revascularization procedure. No cause of death was reported in 23 patients. Of those with a known cause, most were of cardiac origin (39 out of 50 deaths, 78%). Only six deaths were documented non-cardiovascular.
Revascularization procedures during follow-up were performed in 818 patients (16·3%): 595 re-PTCA (11·8%) and 223 coronary bypass operations (4·4%). The rates of repeat revascularization were similar in all groups, except in patients with a creatine kinase-MB or creatine kinase ratio d10, of whom only 7·6% underwent revascularization during follow-up ( Table 2 ). The combined death, reinfarction and reintervention rates at 6 months were similar among all groups (18·4%), except for a lower rate in patients with the highest creatine kinase-MB or creatine kinase ratio after the index intervention. In order to assess whether the higher event rates during follow-up in patients with moderately elevated creatine kinase-MB or creatine kinase ratios were related to differences in baseline characteristics, multivariable analyses were performed using logistic regression analysis. Mortality during follow-up, between 48 h and 6 months after the procedure, appeared associated with the log enzyme ratio, a history of heart failure and age ( Table 5 ). The combined end-point of death and myocardial infarction was associated with an increased log enzyme ratio, a history of heart failure or bypass surgery, age, and with enrolment in the CAPTURE and EPIC studies, relative to EPILOG (Table 4) . Revascularization during follow-up was performed more frequently in patients with a history of diabetes or hypertension, but less frequently in those with previous infarction or single vessel coronary artery disease. Patients in CAPTURE and EPIC underwent subsequent revascularization procedures more frequently.
Discussion
In the present series of more than 5000 patients undergoing PTCA, periprocedural enzyme elevation appeared to be associated with impaired outcome at 6 months follow-up. A higher incidence of myocardial infarction or death was observed at 1 month and 6 months follow-up, both in patients with periprocedural infarction, defined by creatine kinase-MB or creatine kinase values exceeding three times the upper limit of normal, but also in patients with minimal myocardial damage, defined as a periprocedural creatine kinase-MB or creatine kinase ratio between 1 and 3 times normal. These differences remained statistically significant after Causes of death in patients with different levels of creatine kinase-MB or creatine kinase elevation after PTCA. Cardiac mortality rate in % between brackets. 
Odds ratios (confidence intervals) for prediction of death, death or myocardial infarction and death, myocardial infarction or revascularization. For each end-point or combined end-point data are presented for the significant predictors in the multivariable model. Note that patients with a history of myocardial infarction and patients with single vessel disease had a lower probability for subsequent revascularization.
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adjustment for clinical and angiographic patient characteristics, and also in patients who had a successful procedure according to the operator, without implantation of a stent. Marked enzyme elevation (creatine kinase-MB or creatine kinase ratio d10) was associated with increased mortality but not with an increased risk of recurrent infarction or reintervention.
The most frequent causes of death in the present series were myocardial infarction, sudden death or death associated with repeat PTCA or bypass surgery (Table  3) . Heart failure, which is a common cause of death after myocardial infarction, was rarely the cause of death in patients with elevated creatine kinase or creatine kinase-MB ratios in association with the PTCA procedure. These observations indicate that subsequent cardiovascular events were not caused by extensive loss of myocardial tissue. Most periprocedural infarcts were so small that myocardial function was preserved. This is particularly true for patients with minimal myocardial damage (creatine kinase-MB or creatine kinase ratio 1-3). These observations may be explained by different pathophysiological mechanisms. First, small infarcts, which occurred at the time of PTCA, with small areas of necrosis might provide a substrate for arrhythmias and sudden death [6, 7, [10] [11] [12] [13] . Indeed, death was sudden in 28% of patients in whom the cause of death was reported ( Table 4 ). The association of small infarcts and subsequent sudden death was even more prominent in another study with longer follow-up, and accordingly longer exposure to such risk [12] . Second, minimal (creatine kinase or creatine kinase ratio 1-3) or modest (creatine kinase-MB or creatine kinase ratio 3-10) myocardial damage during the PTCA procedure might be an expression of vascular instability which continues to be present and therefore causes subsequent plaque rupture and/or thrombotic events such as myocardial infarction, sudden death or death during revascularization procedures. As such, minimal or modest myocardial damage at the time of PTCA (as in the present study) may have a pathophysiology in common with patients with minimal myocardial damage with unstable angina at hospital admission, who have an impaired outcome both in hospital and during follow-up [14] [15] [16] [17] . Third, it should be appreciated that patients with minimal or modest periprocedural myocardial damage have more extensive coronary disease and more complex lesion characteristics than those without enzyme elevation (Table 1) . Thus periprocedural myocardial damage and impaired long-term outcome might be a result of more severe coronary disease. However, the relationship between periprocedural myocardial damage and impaired outcome remained statistically significant after correction for differences in clinical and angiographic baseline characteristics by multivariable analyses (Table 5 ). This suggests that factors other than those mentioned above also contribute to the increased risk of death and recurrent infarction after minimal or modest myocardial damage at the time of PTCA.
The increased risk of subsequent death or myocardial infarction in patients with minimal or modest enzyme elevation after PTCA has been reported by other investigators [6] [7] [8] 21] . However, such a relationship was not observed in patients undergoing coronary atherectomy in one trial [9] , although directional coronary atherectomy does cause minimal or modest enzyme elevation in a significant number (approximately one third) of patients. Others, however, reported increased mortality at follow-up in an earlier study with directional atherectomy [18] . In patients undergoing atherectomy, distal coronary emboli may be the result of mechanical debris from the vessel wall caused by the atherectomy cutting device. Such patients will be at risk for arrhythmias, but may not be at risk for recurrent vascular instability and future thrombotic events. Also patients with a major infarct (creatine kinase-MB or creatine kinase ratio d10) often have a different pathophysiology. In many of these patients the infarct was a complication of the PTCA procedure, caused by a major dissection, but without subsequent vascular instability. In contrast, the minimal or modest myocardial damage as observed in the present series in patients treated with balloon angioplasty and stents may result in arrhythmias and sudden death, but may also be a reflection of prolonged vascular instability causing thrombosis and subsequent myocardial infarction or death. This hypothesis is in agreement with the observation that recurrent infarction was more frequent in patients enrolled in CAPTURE and EPIC compared with EPILOG (Table 4) . Indeed, the former studies selected patients with unstable angina [1, 2] , while more elective cases were selected in the latter [3] . Additional studies may elucidate the pathophysiology of minimal and modest myocardial damage associated with percutaneous coronary intervention. The data presented in this paper indicate that periprocedural enzyme elevations are not mere 'enzyme leaks', but rather a cause or a marker of subsequent risk for myocardial infarction and death. Prevention of such periprocedural myocardial damage is likely to be of clinical benefit! Treatment with abciximab was associated with an approximately 50% reduction in death and myocardial infarction associated with the PTCA procedures and at 30 day follow-up [1] [2] [3] . The reduction in such events was maintained at 6 months, and was even more prominent at 3 years in EPIC [19] . A combined analysis of all studies with abciximab in patients undergoing coronary intervention revealed a 30% relative reduction of mortality at 6 months in patients treated with this platelet aggregation inhibitor compared with placebo [20] . These observations support the notion that reduction by abciximab of periprocedural creatine kinase-MB elevation is of clinical importance and does improve the outcome of patients undergoing PTCA with or without stent.
Since patients with minimal or modest elevation of creatine kinase-MB or possibly other myocardial proteins after coronary angioplasty, do carry an increased risk for subsequent events, a few practical measures should be considered. Systematic analysis of creatine kinase-MB, or perhaps troponin I or troponin T, should be performed in all patients after PTCA or stent implantation to assess the risk for future events. Patients with signs of minimal or modest myocardial damage, who are at increased risk for subsequent events, should be instructed specifically to seek immediate help whenever symptoms reoccur in the subsequent days or months. Prompt recognition and treatment of recurrent clinical instability in such patients may help to avoid serious events such as myocardial infarction or death. Most patients currently leave hospital one day after an apparently successful PTCA procedure. Patients with minimal or modest myocardial damage might be observed in hospital for an additional few days, since the risk for recurrent events is highest at that time (Fig. 2) . However the rate of death or myocardial infarction in these patients is only 1 to 2% at 4 days after the procedure. Thus early discharge with careful instruction to report recurrent symptoms and immediate readmission of symptomatic patients may be equally effective. Finally, patients with minimal or modest myocardial damage after PTCA might benefit from systematic treatment with beta-blockers, or from prolonged intensive antithrombotic therapy with ticlopidine, clopidogrel or oral glycoprotein IIb-IIIa receptor blockers. The latter concept should be investigated in prospective studies.
